These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 2119417)
21. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Jay RH; Rampling MW; Betteridge DJ Atherosclerosis; 1990 Dec; 85(2-3):249-56. PubMed ID: 2129320 [TBL] [Abstract][Full Text] [Related]
22. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine. Kume N; Kita T; Mikami A; Yokode M; Ishii K; Nagano Y; Kawai C Circulation; 1989 May; 79(5):1084-90. PubMed ID: 2496935 [TBL] [Abstract][Full Text] [Related]
23. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Hoogerbrugge N J Intern Med; 1998 Aug; 244(2):143-7. PubMed ID: 10095800 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Hunninghake DB; Mellies MJ; Goldberg AC; Kuo PT; Kostis JB; Schrott HG; Insull W; Pan HY Atherosclerosis; 1990 Dec; 85(2-3):219-27. PubMed ID: 2129319 [TBL] [Abstract][Full Text] [Related]
25. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I. Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804 [TBL] [Abstract][Full Text] [Related]
26. The effect of pravastatin in relation to low density lipoprotein receptor activity. Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022 [TBL] [Abstract][Full Text] [Related]
27. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study. Athyros VG; Papageorgiou AA; Demitriadis DS; Kontopoulos AG Curr Med Res Opin; 2001; 17(4):267-72. PubMed ID: 11922400 [TBL] [Abstract][Full Text] [Related]
28. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758 [TBL] [Abstract][Full Text] [Related]
29. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Ismail F; Corder CN; Epstein S; Barbi G; Thomas S Clin Ther; 1990; 12(5):427-30. PubMed ID: 2125243 [TBL] [Abstract][Full Text] [Related]
30. Rational therapy of familial hypercholesterolemia. Reynolds GA Circulation; 1989 May; 79(5):1146-8. PubMed ID: 2496938 [No Abstract] [Full Text] [Related]
31. Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588 [TBL] [Abstract][Full Text] [Related]
32. Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270 [TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia. Mabuchi H; Koizumi J; Kajinami K Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Leitersdorf E; Muratti EN; Eliav O; Peters TK Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807 [TBL] [Abstract][Full Text] [Related]
36. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Leren TP; Hjermann I; Berg K; Leren P; Foss OP; Viksmoen L Atherosclerosis; 1988 Oct; 73(2-3):135-41. PubMed ID: 3056429 [TBL] [Abstract][Full Text] [Related]
37. Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia. Ebeling T; Turtola H; Voutilainen E; Uusitupa M; Pyörälä K; Reijonen T Ann Med; 1992 Apr; 24(2):121-7. PubMed ID: 1610539 [TBL] [Abstract][Full Text] [Related]
38. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745 [TBL] [Abstract][Full Text] [Related]
39. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Sjouke B; Langslet G; Ceska R; Nicholls SJ; Nissen SE; Öhlander M; Ladenson PW; Olsson AG; Hovingh GK; Kastelein JJ Lancet Diabetes Endocrinol; 2014 Jun; 2(6):455-63. PubMed ID: 24731671 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. Tonstad S; Knudtzon J; Sivertsen M; Refsum H; Ose L J Pediatr; 1996 Jul; 129(1):42-9. PubMed ID: 8757561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]